All terms in HP

Label Id Description
Increased urinary 3-methylhistidine HP_0410317 [Increased concentration of 3-methylhistidine in the urine.]
Abnormal urinary 3-methylhistidine level HP_0410316 [Abnormal amount of 3-methylhistidine in the urine.]
prominent PATO_0001482 [A quality inhering in a bearer by virtue of the bearer's standing out or projecting beyond a surface or line.]
Hyposegmentation of neutrophil nuclei in CSF HP_0410311 [Hyposegmented (hypolobulated) or bilobed neutrophil nuclei in the cerebrospinal fluid.]
Abnormality of neutrophil morphology in CSF HP_0410310 [An abnormal form or size of neutrophils in the cerebrospinal fluid.]
aplastic PATO_0001483 [Absence of an organ, tissue or cell due to failure to develop from a primordium or precursor cell.]
agenesis PATO_0002291 [Absence of a tissue or organ due to failure to develop.]
sloped PATO_0001481 [A shape quality inhering in a bearer by virtue of the bearer's having an oblique or slanted direction.]
Hypersegmentation of neutrophil nuclei in CSF HP_0410312 [An excessive division of the lobes of the nucleus of a neutrophil in the cerebrospinal fluid.]
Alpha-gal allergy HP_0410319 [Hypersensitivity in form of an adverse immune reaction against alpha-gal.]
Decreased urinary 3-methylhistidine HP_0410318 [Decreased concentration of 3-methylhistidine in the urine.]
cellular motility PATO_0001488 [A cellular quality inhering in a cell by virtue of whether the bearer exhibits the ability to move spontaneously.]
detached from PATO_0001453 [An attachment quality inhering in a bearer by virtue of the bearer's lacking connection or association with another entity.]
Complete or near-complete absence of specific antibody response to meningococcus vaccine HP_0410304 [The inability to synthesize postvaccination antibodies against a meningococcus antigen, as measured by antibody titer determination following vaccination.]
Decreased specific antibody response to protein-conjugated polysaccharide vaccine HP_0410302 [A reduced ability to synthesize postvaccination antibodies against protein-conjugated polysaccharides in vaccines, as measured by antibody titer determination following vaccination.]
Complete or near-complete absence of specific antibody response to Haemophilus influenzae type b (Hib) vaccine HP_0410303 [The inability to synthesize postvaccination antibodies against a Haemophilus influenzae type b (Hib) antigen, as measured by antibody titer determination following vaccination.]
Partial absence of specific antibody response to meningococcus vaccine HP_0410306 [A reduced ability to synthesize postvaccination antibodies against a meningococcus antigen, as measured by antibody titer determination following vaccination.]
Partial absence of specific antibody response to Haemophilus influenzae type b (Hib) vaccine HP_0410305 [A reduced ability to synthesize postvaccination antibodies against a Haemophilus influenzae type b (Hib) antigen, as measured by antibody titer determination following vaccination.]
Complete or near-complete absence of specific antibody response to unconjugated pneumococcus vaccine HP_0410300 [The inability to synthesize postvaccination antibodies against a pneumococcus antigen, as measured by antibody titer determination following vaccination.]
Decreased specific antibody response to polysaccharide vaccine HP_0410299 [A reduced ability to synthesize postvaccination antibodies against polysaccharides in vaccines, as measured by antibody titer determination following vaccination.]